94 results about "Deoxyadenosine" patented technology

Oral formulations of pharmaceuticals are provided with enhanced bioavailability by targeting specific regions of the gastrointestinal tract. Particularly, water soluble and acid-labile drugs such as cytidine analogs (e.g., decitabine) and 2'-deoxyadenosine analogs (e.g., pentostatin) are formulated with pH-sensitive polymers so that these drugs are preferably absorbed in the upper regions of the small intestine, such as the jejunum. In addition, drugs with poor oral bioavailability such as camptothecin compounds (e.g., 9-nitro-camptothecin) can also be formulated using similar strategies in order to significantly improve their oral bioavailability. These formulations can be used to treat a wide variety of diseases or conditions, such hematological disorders, benign tumors, cancer, restenosis, inflammatory diseases, and autoimmune diseases.

The present invention provides for a topical composition that includes a topical carrier and an adenosine deaminase inhibitor. Suitable specific adenosine deaminase inhibitors include, e.g., deoxycoformycin (dCF), deoxyadenosine (dAdo), cladrabine (CdA), fludarabine (F-Ara-A), cytrabine (Ara-C), and thioguanine. The present invention also provides for a method to treat lymphocyte mediated skin diseases and to alleviate symptoms associated with such skin diseases. The method includes topically administering the composition to a mammal in need of such treatment. The present invention also provides for kits and syringe systems that include the adenosine deaminase inhibitor.

A method for artificially culturing north cordyceps to increase the contents of its physiological active components (cordyceptic acid, cordycepin and cordyceptic polyose) includes such steps as washing fresh wild north cordyceps, section, regulating pH of culture medium to 6-7, sterilizing, shaping slant, slant culturing at 20-25 deg.C for 7-10 days, regulating pH of liquid culture medium to 6-7,sterilizing, inoculating, culturing, preparing solid culture medium from rice and sorghum grains, inoculating, and culturing at 25-29 deg.C for 40-60 days.

The invention relates to a method for testing a sequence of a nucleic acid single molecule in the technical field of biology, which comprises the following steps: respectively detecting Raman spectrumsignals of deoxyadenosine 5'-phosphoric acid, deoxyguanosine 5'-phosphoric acid, deoxycytidine 5'-phosphoric acid, deoxythymidine 5'-phosphoric acid, methyldeoxycytidine 5'-phosphoric acid, adenosine5'-phosphoric acid, vernine 5'-phosphoric acid, cytidine 5'-phosphoric acid and uridine 5'-phosphoric acid and establishing a standard curve; cutting a nucleic acid molecule to be detected by exonclease and detecting the Raman spectrum signal transmitted by a cut product when passing through a zero mode waveguide by the trigger of a laser; converting the Raman spectrum signal obtained in the step2 into concrete ribotide according to the standard curve obtained in the step 1 and obtaining the concrete sequence of the nucleic acid molecule to be detected by combining the cutting direction of the exonclease. The method can directly detect a natural nucleic acid sequence without a mark and has high detecting speed and detecting quality and low detecting cost.

An application of 3'-deoxyadenosine in preparing the medicine for decreasing blood fat, especially the serum triglyceride, is disclosed.

The invention relates to a method for detecting bacteria, in particular to a method for detecting enteritis pathogenic bacteria. The method comprises the following steps of: (1) extracting DNA (Deoxyribonucleic Acid) of one or more bacteria samples; (2) amplifying full length of 16S rDNA (ribosomal DNA) of a sample by using a primer of 16S rDNA of bacteria; (3) breaking an amplified PCR (Polymerase Chain Reaction) product; (4) repairing ends of the broken product from each bacteria sample and connecting deoxyadenosine at the end 3' of the product, and then connecting different PCR-free joints; (5) sequencing a connection product by using a second-generation sequencing technology to obtain a sequence of the connection product; and (6) comparing the sequence with 16S rDNA reference sequences of all existing bacteria to determine types of bacteria existing in each sample.

This invention relates to pharmaceutical formulations and formulation strategies of protides (phosphoramidate derivatives of nucleosides) and, in particular, protides useful in the treatment of cancer, such as NUC-3373 (5-fluoro-2′-deoxyuridine-5′-O-[1-naphthyl (benzoxy-L-alaninyl)] phosphate) and NUC-7738 (3′-deoxyadenosine-5′-O-[phenyl(benzyloxy-L-alaninyl)] phosphate). In particular, the invention relates to formulations that comprise a polar aprotic solvent, for example, dimethyl acetamide (DMA).

A process for extracting complex cordycepin includes such steps as immersing the powdered cordyceps in water for 8-14 hr, extracting by alcohol or by decocting and alcohol deposition, filtering to obtain liquid medicine, concentrating reflux of alcohol, eluting with ionic column, concentrating, cold storage at 0 deg.C for 24 hr, crystallizing, and recrystallizing with n-butanol. The cordycepin contains 2'-deoxyadensine and 3'-deoxyadenosine compound and has high anticancer action.

A method for individuating with high sensitivity and specificity ADA metabolites from dried blood spot. The method described herein can be used to extract Adenosine and Deoxyadenosine from a sample under conditions that permit concurrently extracting other metabolites, such as amino acids, free carnitine, or acylcarnitines. For example, harsh extraction conditions (such as extreme acidity and high temperature) can be avoided. The method can be used, along with other neonatal screenings, on blood samples and preferably on dried blood spots (Guthrie cards) and more preferably on Guthrie cards obtained in the II-IV day of life. The method is reliable and reproducible, easy to perform and gives a definitive response within a short time (1-2 days). One or more kit for use in the method.

A method of detecting N-glycosylase activity in a sample involves incubating an oligodeoxyribonucleotide substrate containing a deoxyadenosine or deoxyuridine residue with the sample to be tested such that the N-glycosylase, if present, hydrolyzes the deoxyadenosine or deoxyuridine residue to result in an N-glycosylase product having an abasic site. A primer is annealed to the N-glycosylase product, and the primer is extended with a DNA polymerase, such as Taq DNA polymerase, that pauses at abasic sites. The resulting extension products are melted from the N-glycosylase product, allowed to form hairpins due to self-complementarity, and further extended in the presence of labeled precursors to result in labeled products. Extension products synthesized from undigested substrate as template do not result in labeled products. Thus, detection of labeled products results in detection of N-glycosylase activity. Oligodeoxyribonucleotide substrates, primer, and positive controls and a kit for N-glycosylase assay are also disclosed.

The invention discloses a method for producing deoxyadenosine by a bioconversion method, comprising the following steps of: inoculating swiss lactobacillus seed liquid in a fermentation medium for fermentation and culture, thus obtaining a crude strain; crushing the crude strain to prepare a cell homogenates; and adding a deoxythymidine and a adenine in the cell homogenates for enzymatic reaction, thus obtaining the deoxyadenosine; the fermentation medium comprises the following substances by weight portion: 10-20 portions of dextrose, 1-5 portions of peptone, 10-25 portions of corn gluten, 1-2 portions of citric acid amino, 1-2 portions of potassium phosphate dibasic, 5-10 portions of sodium sulfate, 0.02-0.4 portions of manganese sulfate and 1000 portions of water; and the granularity of the adenine is less than or equal to 10 microns. The method for producing the deoxyadenosine by the bioconversion method sufficiently utilizes the high effectiveness, specificity and moderateness of the enzyme, and has the advantages of high selectivity, moderate condition, simple process, low cost, small pollution and the like compared with the traditional chemical synthesis method.

The invention discloses a method for converting escherichia coli to produce 2'-deoxyadenosine. Escherichia coli thallus with high nucleoside phosphorylase activity is directly adopted as an enzyme source to mix with deoxythymidine which is taken as a conversion reaction substrate as well as adenine to carry out conversion reaction to synthesize 2'-deoxyadenosine. The method has the advantages of simple process, high conversion ratio, low production cost and gentle reaction conditions; moreover, the by-products are fewer, green and pollution-free, and the products are easy to separate and purify. A conversion ratio of adenine is over 72.5%. Besides, the 2'-deoxyadenosine is separated and purified by adopting a method of crystallization and recrystallization, so that the purity of the 2'-deoxyadenosine is over 99%.

The present invention relates to a method for purification and/or concentration of natural cobalamins by adsorption on insoluble materials containing carboxylic groups. Especially the method comprises providing a first solution comprising at least one type of natural cobalamins, providing an adsorbent material comprising carboxylic groups capable of making specific interaction with said natural cobalamins, contacting said first solution comprising at least one type of natural cobalamins with said adsorbent material, whereby at least a part of said at least one type of natural cobalamins becomes adsorbed and/or bound to said adsorbent material, and elution of said at least one type of natural cobalamins from said adsorbent material, hereby obtaining a concentrated solution comprising at least one cobalamin. The natural cobalamins can be one or more of the natural cobalamins 5'-deoxy-5'-adenosyl-Cobalamin (adenosyl- Cbl, Ado Cbl), methyl-cobalamin (methyl-Cbl, Me Cbl) and aquo-cobalamin (aquo-Cbl, H2O Cbl).

The invention discloses a synthetic method for cordycepin. The method comprises the following steps: with adenosine as a starting material, subjecting adenosine and Mattock's bromide to bromination in a reaction solvent of acetonitrile and/or ethyl acetate during implementation of hydroxyl protection so as to obtain two products, i.e., 5'-[2,5,5-trimethyl-1,3-dioxolane-4-one-2-yl]-3'-bromo-3'-deoxy-2'-O-acetyl adenosine and 5'-[2,5,5-trimethyl-1,3-dioxolane-4-one-2-yl]-2'-bromo-2'-deoxy-3'-O-acetyl adenosine; then removing protective groups so as to obtain 3'-bromo-3'-deoxy-adenosine hydrochloride; and subjecting 3'-bromo-3'-deoxy-adenosine hydrochloride to debromination so as to obtain 3'-deoxyadenosine, i.e., cordycepin. The synthetic method provided by the invention is simple to operate, has short reaction steps and does not need purification in the process of reaction; and the purity and each index of the obtained cordycepin product are better than a currently commercially available cordycepin product.

The invention discloses application of 3'-deoxyadenosine in reducing weight, enhancing insulin sensitivity and improving lipid metabolism, and particularly relates to the application of the 3'-deoxyadenosine shown in a formula (1), which is used as a weight reduction pill, an insulin sensitizer and a blood fat regulator, in medicaments and/or health care products, in particular to the application of the 3'-deoxyadenosine in preventing and treating hypercholesterolemia, mixed type hyperlipidemia, and dyslipoproteinemia.

The invention belongs to the technical field of medicines, and discloses a synthetic method and an application of an alkynyl modified deoxyadenosine phosphoramidite monomer compound. According to themethod, an N6 position of deoxyadenosine is carboxylated and modified by alkynyl to obtain an intermediate, and protection of a 5'-terminal hydroxyl group and two-step reaction of 2'-phosphoramidite are implemented to obtain the alkynyl modified deoxyadenosine phosphoramidite monomer compound. Solid-phase synthesis of DNA (deoxyribonucleic acid) is implemented, and the DNA is leaded into oligonucleotide in a fixed point manner to obtain artificial genomic loci alkynyl modified oligonucleotide. The alkynyl modified deoxyadenosine phosphoramidite monomer compound is applied to oligonucleotide alkynyl modification, the method is simple, yield is considerable, new ideas and high-value intermediates are provided for follow-up DNA functionalization, and the compound is wide in application prospects.

The invention relates to cloning, sequencing, analysis and functional research of a biosynthesis gene cluster of 2'-chloropentostatin and 2'-amino-2'-deoxyadenosine and application thereof. The 2'-chloropentostatin is a natural product produced by actinomadura madurae ATCC 39365 and is used for treating leukemia; the 2'-amino-2'-deoxyadenosine is a natural product of RNA (ribonucleic acid) viruses of anti-mycoplasma virus, measles virus and the like. The whole gene cluster contains 13 genes, wherein five genes are related with synthesis of the 2'-chloropentostatin; four genes are related with synthesis of the 2-amino-2'-deoxyadenosine; four genes are related with transfer and regulation of the 2'-chloropentostatin and the 2-amino-2'-deoxyadenosine. The biosynthesis of the 2'-chloropentostatin and the 2-amino-2'-deoxyadenosine is blocked or improved by the genetic manipulation on the biosynthesis gene. The gene and the protein thereof can be applied to the gene engineering, protein expression, enzyme catalytic reaction and the like of the compound, and be used for looking and finding compounds, genes and proteins for medicines, industry or agriculture.

The present invention provides an oligodeoxynucleotide containing humanized K type CpG oligodeoxynucleotide and poly deoxyadenylate, wherein the poly deoxyadenylate is placed on the 3′-side of the humanized K type CpG oligodeoxynucleotide. In addition, the present invention provides a complex containing the aforementioned oligodeoxynucleotide and β-1,3-glucan.

The invention discloses a self-assembled nano material. formed by nucleic acid or nucleotide, an amino acid derivative or polypeptide and copper ions through self-assembly. The type of the amino acidderivative is lysine, histidine, methionine or cysteine; the chiral configuration is L-shaped or D-shaped; the polypeptide contains histidine, methionine, lysine or cysteine; the length of the peptideis 2 peptide-40 peptide; the nucleic acid is DNA; the molar ratio of guanine deoxynucleotide in DNA is 10%-100%, the total number of the nucleotides is 4-59, and the nucleotide is guanosine-5'-monophosphate, adenosine-5'-monophosphate, cytidine-5'-monophosphate, uridine-5'-monophosphate, deoxyguanosine-5'-monophosphate, deoxyadenosine-5'-monophosphate, deoxycytidine-5'-monophosphate or thymidine-5'-monophosphate. According to the invention, the simulated enzyme catalytic reaction can be monitored through a light absorption or fluorescence photometer.

The invention relates to medical novel applications of cordycepin (3'-deoxyadenosine), and more specifically relates to applications of cordycepin used for preparation of medicines used for preventing and treating atherosclerosis and atherosclerosis related diseases. It is confirmed by pharmacodynamic experiments that: cordycepin is capable of inhibiting formation of ApoE-/- mice aorta atherosclerotic plaques significantly, reducing serum TC, TG, and LDL-c contents of animals with hyperlipidemia, increasing total antioxidant capacity and SOD activity of animal serum, reducing MDA content, reducing contents of serum interleukin 2 and interleukin 8 significantly, and inhibiting inflammation. It is confirmed by cell experiments that: cordycepin is capable of inhibiting uptake of mononuclear cell RAW267.4 on cholesterol significantly, and promoting flowing of cholesterol out from cells.

The invention discloses a ruthenium polypyridyl complex and a method for preparing the same and an application thereof in antineoplastic medicines. The ruthenium polypyridyl complex is a ruthenium(II) complex which respectively takes 3'-deoxyadenosine or 2'-deoxyadenosine as a main ligand and bipyridyl(bpy), dimethyl bipyridyl(dmbpy) and phenanthrolines(phen) as auxiliary ligands. In the invention, firstly ruthenium trichloride, poly-pyridine and lithium chloride are dissolved in DMF and subjected to heating reflux under the argon shield for 8h to prepare crystals, and the crystals and deoxyadenosine are dissolved in absolute ethyl alcohol and subjected to reflux under the argon shield and at a temperature of 90 DEG C for 5h, and the solid coarse product is obtained through a column chromatography purification reaction, and the ruthenium polypyridyl complex is obtained. The ruthenium polypyridyl complex of the invention can be used as a chemotherapeutic drug to treat tumors.

A method for producing cladribine (2-chloro-2′-deoxyadenosine) comprising the steps of:

a) reaction of 2-deoxyuridine with 2-chloroadenine, in the presence of uridine phosphorylase (UPase) and purine nucleoside phosphorylase (PNPase) in an aqueous reaction medium possibly containing up to 40% v/v of an aprotic dipolar solvent, to obtain cladribine dissolved in said reaction medium;

b) isolation of the cladribine by precipitation by means of concentration and alkalinisation of the reaction medium up to pH 11.5-12.5.

The invention provides a method for determining nucleotide metabolites in a filter paper dried blood spot. The nucleotide metabolites comprise adenosine, 2'-deoxyadenosine, guanosine, 2'-deoxyguanosine, inosine and 2'-deoxyinosine. The method comprises the following steps: 1) performing extraction treatment on a to-be-detected filter paper dried blood slice in an extraction working solution to obtain an extraction solution containing the nucleotide metabolite; 2) carrying out liquid chromatography-mass spectrometry detection on the extract liquor; and 3) determining the yield of the nucleotidemetabolites in the filter paper dried blood spot based on a liquid chromatography separation-mass spectrometry detection result. According to the detection method provided by the embodiment of the invention, six nucleotide metabolites in the filter paper dried blood spot can be simultaneously detected, and the detection method is used for scientific research or synchronous screening and diagnosisof ADA and PNP diseases, so that the detection cost is reduced, and the efficiency is improved. The method has the advantages of high sensitivity, strong specificity and high accuracy.

The invention relates to a non-coding sequence of deoxyribonucleic acids comprising at least one sequence motif N¹N²CGN³N⁴, wherein N is a nucleotide comprising A, C, T, or G, and C is deoxycytidine, G is deoxyguanosine, A is deoxyadenosine and T is deoxy-thymidine for the treatment of viral infections. In particular, the non-coding sequence of deoxyribonucleic acids is used in combination with antiretroviral therapy and/or histone de-acetylase inhibitors.